Compare Gilead Sciences, Inc. (GILD) vs Manchester United PLC (MANU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Manchester United PLC — how do they compare? Gilead Sciences, Inc. trades at $147.01 (market cap $182.40B), while Manchester United PLC trades at $20.21 (market cap $3.51B). The key difference: Gilead Sciences, Inc. is far larger — about 52× Manchester United PLC's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Manchester United PLC for 109 Days on average.
| GILD | MANU | |
|---|---|---|
Market Cap | $182.40B | $3.51B |
Volume | 4,469,821 | 412,769 |
Sector | Health | Media |
52-Week High | $155.80 | $24.19 |
52-Week Low | $116.74 | $15.20 |
Typical Hold Time | 111 Days | 109 Days |
Enterprise Value | $205.46B | $4.33B |
Dividend Yield | 2.23% | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
Manchester United (MANU) trades at $20.25, down 0.74% on the day, amid a bearish technical signal. The company reported a net loss of $33.02 million for 2025 despite revenue of $666.51 million, with negative profit margins and return metrics. Recent news highlights a valuation gap, with the market cap at $3.6 billion versus a Forbes estimate of $7.2 billion, while operational performance shows some improvement with a return to Champions League football.
The outlook remains cautious; while the valuation discount presents a potential opportunity, persistent losses and high debt levels pose significant risks. Analyst sentiment is mixed with a 40% buy rating, but fundamental challenges in achieving sustained profitability are key concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →
